NCT04726527

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

Clinical Evaluation of Florbetapir F 18 (18F-AV-45) / Determinants of Neurodegenerative Decline in Primary Progressive Aphasia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 48 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Detailed description

This study is being done to examine the usefulness of Positron Emission Tomography (PET) imaging with florbetapir F 18 as a biomarker in the identification of amyloid-ß peptide (Aß) in the brain. Amyloid-ß peptide (Aß) accumulates in the brains of patients with Alzheimer's disease. Florbetapir F 18 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera. The development of biomarker and imaging studies that track the development of PPA and reflect the change in people's bodies may help other people who have a similar medical problem in the future.

Conditions

• Primary Progressive Aphasia
• Alzheimer Disease
• Dementia

Interventions

Type	Name	Description
DRUG	Florbetapir F 18	A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
DEVICE	Positron Emission Tomography	PET Scan for brain imaging

Timeline

• Start date: 2012-03-15
• Primary completion: 2015-09-02
• Completion: 2017-02-28
• First posted: 2021-01-27
• Last updated: 2024-10-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study